Molecular diagnostics company Seegene has launched STAgora, a platform designed for infectious disease analytics.
The system integrates diagnostic data with statistical tools to transform how outbreaks are detected and managed globally.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It offers real-time visualisation of infectious disease trends across municipal, national and continental scales, drawing on diagnostic test results.
Designed as an intelligence system, the platform equips healthcare professionals with immediate, structured reports and statistical insights presented through customisable dashboards and real-time alerts.
Beyond tracking individual cases, it allows users to monitor disease outbreaks across chosen regions, both locally and globally.
This functionality enhances situational awareness and supports data-driven public health decisions.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFeaturing more than 40 statistical tools, STAgora facilitates early detection of unusual pathogen patterns and supports predictive modelling for seasonal trends and potential outbreaks.
These tools include capabilities for monitoring individual infections, analysing symptom-based co-infections, and calculating infection rate trends in real-time, turning raw data into actionable intelligence for proactive measures.
Unlike conventional systems that rely on retrospective data, STAgora leverages real-time PCR-based diagnostics to provide immediate insights into pathogen spread.
Its AI-driven algorithms also enable forecasting of potential future outbreaks, enhancing preparedness.
When integrated with Seegene’s syndromic quantitative PCR technology, the platform provides detailed insights into both single-pathogen infections and multi-pathogen co-infections.
Seegene’s chief global sales and marketing officer and executive vice-president Daniel Shin said: “During the Covid-19 pandemic, we saw firsthand how crucial accurate and timely interpretation of diagnostic data was in shaping public health policies and clinical outcomes.
“Now, as we confront increasingly complex threats such as antimicrobial resistance, viral mutations and co-infections, the ability to deliver actionable insights from diagnostic data is becoming a cornerstone of clinical innovation and a vital pillar of global health security.”
In 2023, Seegene USA partnered with Microbix Biosystems to provide QAPs for monitoring the accuracy of Seegene Novaplex and Allplex assays in the US.
